- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.07. | Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma) | 1 | Cision News | ||
| 22.06. | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million | 2 | Cision News | ||
| 22.06. | Curasight A/S announces its intention to carry out a directed issue of shares | 1 | Cision News | ||
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 08.06. | Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT in Aggressive Brain Cancer (Glioblastoma) | 456 | PR Newswire | COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial... ► Artikel lesen | |
| 28.05. | CURASIGHT: Interim report Q1 2026 | 2 | Cision News | ||
| 26.04. | CURASIGHT: Major Shareholding Notification - share transfer and ownership restructuring - related party transaction | 2 | Cision News | ||
| 25.03. | Resolutions of the Annual General Meeting 2026 of Curasight A/S | 2 | Cision News | ||
| 10.03. | CURASIGHT: Notice of Annual General Meeting 2026 | 1 | Cision News | ||
| 06.03. | Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade | 1 | Cision News | ||
| 17.02. | Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston | 334 | PR Newswire | COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ -- Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies... ► Artikel lesen | |
| 12.01. | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas | 532 | PR Newswire | Clear uptake of uTREAT in aggressive brain cancer (glioblastoma)Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and... ► Artikel lesen | |
| 05.01. | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | 417 | PR Newswire | COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" - (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain... ► Artikel lesen | |
| 18.12.25 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT in Brain Cancer | 1.121 | PR Newswire | Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT belonging to Curasight's treatment platformNo patient safety issues were reported The dosing... ► Artikel lesen | |
| 08.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 08.12.2025 | 982 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.12.2025
Aktien
1 KYG4600C1107 Hope Life International... ► Artikel lesen | |
| 26.11.25 | Curasight's uTREAT Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | 445 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREATSite given green light by European Medicines Agency (EMA) and is now open for patient... ► Artikel lesen | |
| 26.08.25 | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT in brain cancer patients | 362 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 31,630 | 0,00 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| SUMMIT THERAPEUTICS | 13,350 | -4,64 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| QIAGEN | 37,290 | -0,98 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen nach Zahlen zum zweiten Quartal von 43 auf 47 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Die Resultate... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,56 | +0,08 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,390 | -0,06 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 367,40 | -0,35 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 21,625 | 0,00 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,610 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,950 | +1,74 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| KYMERA THERAPEUTICS | 117,37 | +0,10 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| CLIMB BIO | 16,340 | -0,07 % | Climb Bio, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 75,10 | +0,59 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,690 | -1,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,195 | +1,41 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| KINIKSA PHARMACEUTICALS | 76,69 | -0,01 % | Kiniksa auf Wachstumskurs: ARCALYST-Umsatz steigt, Pipeline wird ausgebaut |
Das Unternehmen CURASIGHT A/S kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,925 Euro und damit -2,04 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.